UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension

The European respiratory journal, 2019-01, Vol.53 (1), p.1801906

2019

Volltextzugriff (PDF)

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Chest, 2012-08, Vol.142 (2), p.448-456

2012

Volltextzugriff (PDF)

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry

Chest, 2015-10, Vol.148 (4), p.1043-1054

2015

Volltextzugriff (PDF)

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension

Chest, 2021-01, Vol.159 (1), p.337-346

2021

Volltextzugriff (PDF)

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies

Chest, 2019-08, Vol.156 (2), p.323-337

2019

Volltextzugriff (PDF)

The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension

Chest, 2012-02, Vol.141 (2), p.354-362

2012

Volltextzugriff (PDF)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

The European respiratory journal, 2019-06, Vol.53 (6), p.1802004

2019

Volltextzugriff (PDF)

World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation

The Journal of heart and lung transplantation, 2012-09, Vol.31 (9), p.913-933

2012

Volltextzugriff (PDF)

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance

The Journal of heart and lung transplantation, 2015-03, Vol.34 (3), p.362-368

2015

Volltextzugriff (PDF)

Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?

American journal of respiratory and critical care medicine, 2018-04, Vol.197 (7), p.843-845

2018

Volltextzugriff (PDF)

Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular disease

The Journal of heart and lung transplantation, 2020-08, Vol.39 (8), p.852-853

2020

Volltextzugriff (PDF)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review

The Journal of heart and lung transplantation, 2021-03, Vol.40 (3), p.172-182

2021

Volltextzugriff (PDF)

Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial

Chest, 2023-12, Vol.164 (6), p.1518-1530

2023

Volltextzugriff (PDF)

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

The Journal of heart and lung transplantation, 2020-04, Vol.39 (4), p.300-309

2020

Volltextzugriff (PDF)

Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design

Respiratory research, 2022-12, Vol.23 (1), p.355-355, Article 355

2022

Volltextzugriff (PDF)

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis

The Journal of heart and lung transplantation, 2015-03, Vol.34 (3), p.356-361

2015

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry

Chest, 2010-02, Vol.137 (2), p.376-387

2010

Volltextzugriff (PDF)

Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

The Journal of heart and lung transplantation, 2021-10, Vol.40 (10), p.1172-1180

2021

Volltextzugriff (PDF)

Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension

American journal of respiratory and critical care medicine, 2015-12, Vol.192 (11), p.1345-1354

2015

Volltextzugriff (PDF)

Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension

The Journal of heart and lung transplantation, 2018-03, Vol.37 (3), p.365-375

2018

Volltextzugriff (PDF)

Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study

The Journal of heart and lung transplantation, 2022-03, Vol.41 (3), p.411-420

2022

Volltextzugriff (PDF)

Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials

American journal of respiratory and critical care medicine, 2021-03, Vol.203 (6), p.726-736

2021

Volltextzugriff (PDF)

Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up

Chest, 2021-11, Vol.160 (5), p.1822-1831

2021

Volltextzugriff (PDF)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors

The European respiratory journal, 2017-09, Vol.50 (3), p.1602425-1602425

2017

Volltextzugriff (PDF)

Phenotypes of idiopathic pulmonary arterial hypertension

The lancet respiratory medicine, 2022-10, Vol.10 (10), p.e89-e89

2022

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Aktive Filter

ThemaRespiratory System

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(133)

Publikationsform

Artikel
(134)

Sprache

Englisch
(134)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(134)
Science & Technology
(134)
Humans
(93)
Cardiac & Cardiovascular Systems
(83)
Cardiovascular System & Cardiology
(83)
Male
(59)
Female
(58)
Middle Aged
(56)
Pulmonary Arterial Hypertension
(56)
Surgery
(55)
Pulmonary Hypertension
(51)
Transplantation
(51)
Adult
(40)
Critical Care Medicine
(37)
General & Internal Medicine
(37)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Aged
(28)
Hypertension, Pulmonary - Drug Therapy
(27)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies

The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation

Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance

Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?

Ethical considerations of thoracic transplant and circulatory support during the COVID-19 pandemic: A closer look at pulmonary vascular disease

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review

Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design

Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis

Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry

Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension

Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension

Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study

Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials

Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors

Phenotypes of idiopathic pulmonary arterial hypertension

Aktive Filter

Suchergebnisse filtern